GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
Status:
Recruiting
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and
associated with worse outcomes. While reduced β-cell mass contributes to the insulin
secretory defects that characterizes cystic fibrosis-related diabetes (CFRD), other
modifiable determinants appear operative in the emergence and progression of abnormal glucose
tolerance towards diabetes. Identifying interventions to preserve β-cell function are crucial
for delaying and potentially preventing CFRD development. In this study, we hypothesize that
weekly administration of the long-acting glucagon-like peptide-1 (GLP-1) agonist dulaglutide
will improve defective early-phase insulin secretion and improve glucose tolerance during a
mixed-meal tolerance test.